Hemogenyx Pharmaceuticals Reaches Milestone with First-in-Human CAR-T Therapy for AML

An update from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.

Hemogenyx Pharmaceuticals has announced the administration of its first-in-human dose of HG-CT-1, a proprietary CAR-T cell therapy, for treating relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant milestone in their clinical development program, highlighting progress toward providing a potentially life-saving treatment for AML patients with limited options.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company headquartered in London, with US subsidiaries located in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases and aims to expand the use of bone marrow transplantation for patients with life-threatening conditions. Hemogenyx is working on several product candidates and a platform technology to drive novel product development.

YTD Price Performance: -21.60%

Average Trading Volume: 19,569

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £11.44M

For an in-depth examination of HEMO stock, go to TipRanks’ Stock Analysis page.